about
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinomaNSAIDs modulate clonal evolution in Barrett's esophagus.p16 mutation spectrum in the premalignant condition Barrett's esophagus.Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagusApplication of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storageSelenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.Genetic clonal diversity predicts progression to esophageal adenocarcinoma.The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagusIntegrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett's Esophagus Cohort.High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett's Esophagus.Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagusUse of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's EsophagusProgress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective studyCell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study.Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagusLeukocyte telomere length predicts cancer risk in Barrett's esophagus.Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae.Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus.Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus.Chromosomal instability in Barrett's esophagus is related to telomere shortening.Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.Neosquamous epithelium does not typically arise from Barrett's epithelium.Biomarkers in Barrett's esophagusLongitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagusExtent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus
P50
Q21563424-0F4A0993-4054-48DA-A79D-72D7D1BD310FQ31119674-377560BA-5920-42D5-8530-D525595343C9Q33388259-F589CDE9-897F-418D-806A-AA7BB64F0E95Q33596309-2CFB095F-C7AF-40A2-B661-07FDADAB524EQ33842160-D494FC64-47F8-460E-83AC-1F38F83F39A8Q33902184-FA3E38E2-B438-48F7-949B-C2C0757D78C5Q34213725-FB1F8697-A421-42E6-87E9-14DA76DF5DB7Q34310309-E69D2491-BE8E-428D-8A66-C06757C5655DQ34360062-ECEC832A-C022-443D-AC96-DA7862B7D2D6Q34418880-9B6BADC9-78A2-4F62-93E8-E870F57B4362Q34457732-B9AF385F-0EEE-40F0-86B6-99C1E52B95ACQ34471919-B3904A4D-6AB9-4240-8D67-BAD96622EE7FQ34505745-4B79A3F0-C6E2-48AD-8E8D-E8D6C7D26664Q34542075-393EC52C-7341-422E-9A18-67C272D17777Q34586242-0431321D-4B85-47DC-9443-DFA1BD8250EDQ35112414-A08883B1-23C8-40FC-B9C1-09D1BE0CA177Q35664295-AB7D1824-EF8B-45F9-AC8D-7437EEA30DDAQ35730632-E692D2A4-2A1A-4E96-A086-920327A92EE1Q35778939-2AD40469-7865-48F2-AE62-525E7CAB5903Q35815590-A31ECAF0-8058-4546-ABAE-C17CB2868C79Q35925200-6D6C70FF-7B9C-4300-9E82-A887CE1A1D0FQ36029469-63A5D4B2-C10C-4CEF-95C3-D89F17E24ECEQ36508209-1700B67E-7D8D-478E-9144-18D400CA0ABEQ36629369-91989805-216A-44FC-A4AA-2DA9F414A283Q36983098-C7D897DD-55E5-447D-9BF8-1185F92219B2Q37042894-7D9541C2-8CD6-4894-AF0A-46FD742DD704Q37198249-1A67C50E-F851-4ABD-B832-50037CB4CDE1Q37242084-E57D01FF-5DAE-4214-92A4-0ED1A5A6BAE4Q37524048-F5B33D80-5F56-45C3-A352-8788CC82A87EQ40143227-F8EBA1FC-FE28-4266-BC3B-4225869E659AQ42493566-FD3DFF64-703A-4290-80C4-189A484CBB0DQ42872188-8BBF5CF6-0F62-4D0E-BD5F-2E0A047FF42FQ47365870-BEF07F60-D548-4271-A587-B741AF6003A1Q52562822-0834C2EF-4845-42B0-85EE-DE3B09E727A4Q53343136-63317AC4-0666-4D3D-886B-6965CCA203D5Q53387945-6B2F8DCB-BCF2-496B-B2B5-9325521DB354Q53631319-9BE2C785-33E4-4767-9467-F3B925D23033Q73805094-750E745E-DC93-4926-92C3-6DD6960ED216Q79843913-D17309FF-459A-433B-AAE6-C9663B330557Q79878456-6BB62FBC-5C61-49EE-8F36-FA4B0C2CDB7B
P50
name
Patricia L Blount
@en
type
label
Patricia L Blount
@en
prefLabel
Patricia L Blount
@en